Hyperparathyroidism Secondary Treatment Market Report Covering Market Dynamics And How Businesses May Address Challenging Environment | Robust CAGR of 10.5% over the forecast period (2021-2027).
Secondary hyperparathyroidism (SHPT) is a serious, frequent, and progressive consequence of chronic kidney disease (CRF) characterized by high levels of parathyroid hormone, mineral metabolic problems and an enlarged parathyroid gland. Since the failing kidneys are unable to convert vitamin A to its organic metabolite due to insufficient excretion of phosphate, the body produces insoluble calcium phosphate, resulting in secondary hyperparathyroidism. Bone and joint pain, as well as limb abnormalities, are typical indications and symptoms of the disease. Patients with secondary hyperparathyroidism may have a poor quality of life and a shorter life expectancy due to the disturbances they experience. SHPT is treated with surgery or the use of prescription drugs that help keep parathyroid hormone, calcium, and phosphorus levels within acceptable target ranges. Diabetes and hypertension, according to the National Institute of Diabetes and Digestive and Kidney Diseases, are the two main causes of chronic kidney disease. Patients with CRF, which can be caused by a variety of factors, can develop permanent kidney failure if left untreated.
Get a Sample Covid-19 Impact Assessment Report: https://www.coherentmarketinsights.com/insight/request-sample/1570
One of the key drivers in the global secondary hyperparathyroidism treatment market is the increasing frequency of chronic kidney disease. According to the Centers for Disease Control and Prevention (CDC), 30 million people, or 15% of all adults in the United States, have chronic kidney disease, 48% of whom have significantly reduced kidney function. However, many people ignore this condition. In addition, according to the National Kidney Foundation, chronic kidney disease affects 10% of the world’s population in 2016. In addition, considerable research in the field of nephrology to develop new drugs and therapies for the treatment of secondary hyperparathyroidism fuel the global treatment of secondary hyperparathyroidism. expanding the market. Sanofi SA’s Hectorol capsules are currently conducting phase 3 clinical studies to assess the safety and efficacy of the drug in reducing secondary hyperparathyroidism in juvenile patients with stage 3 and 4 chronic renal failure. December 2017, research on the drug will be completed and it will be commercially available.
Muscle spasms, diarrhea, and nausea, which are usually associated with secondary treatment for hyperparathyroidism, should suffocate the patient. Secondary Hyperparathyroidism Treatment Market expansion.
Due to the increased research and development of innovative therapies and potential drugs for secondary hyperparathyroidism, as well as a high incidence of chronic kidney disease, North America dominates the global secondary hyperparathyroidism treatment market. In 2014, 118,000 people in the United States began treatment for ESRD and 662,000 were on chronic dialysis, according to the Centers for Disease Control and Prevention (CDC). Furthermore, Europe is expected to be the second largest contributor of revenue in the global secondary hyperparathyroidism treatment market, with considerable growth expected in the coming years. This is due to the introduction of new drugs and therapies to treat secondary hyperparathyroidism, as well as the existence of a large population affected by the disease in this area. The European Commission granted Amgen marketing authorization for etecalketide in December 2016 for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease.
Due to the fact that regional companies are undertaking clinical studies for the introduction of new drugs, Asia-Pacific is expected to be the fastest growing area. Kyowa Hakko Kirin China Pharmaceutical Co., Ltd. is conducting Phase 4 clinical research to evaluate the safety and efficacy of Cinacalet, its new lead chemical for the treatment of patients with mild to moderate PTSD. Cinacalet is expected to hit the market by April 2019.
Buy this premium report now to grow your business: https://www.coherentmarketinsights.com/promo/buynow/1570
Reasons to buy this report
• Current and future of the world secondary treatment for hyperparathyroidism market outlook in developed and emerging markets
• The segment which is expected to dominate the market as well as the segment which holds the highest CAGR during the forecast period.
• Regions / countries expected to experience the fastest growth rates during the forecast period
• The latest developments, market shares and strategies used by the main market players
The major companies contributing to the global secondary hyperparathyroidism treatment market are Kyowa Hakko Kirin Co. Ltd., Amgen, Inc., F. Hoffmann-La Roche AG, OPKO Health, AbbVie, Inc., Leo Pharma, Shire, Inc., Deltanoid Pharmaceuticals, Astellas Pharma, Inc., Sanofi SA and KAI Pharmaceuticals.
To maintain their brand reputation and increase their market share, large companies focus on innovation and new product development. Rayaldee was launched by OPKO Health in June 2016 for the treatment of PTSD in people with stage 3 or 4 chronic kidney disease.
Coherent Market Insights is a global market intelligence and consulting organization focused on helping our plethora of clients achieve transformational growth by helping them make critical business decisions. We have our head office in India, an office at Global Financial Capital in the United States, and business consultants in the United Kingdom and Japan. Our clientele includes players from various industries in more than 150 countries around the world. We pride ourselves on serving clients of all backgrounds, from Fortune 500 companies to nonprofits and startups looking to enter the market. We excel in providing unmatched actionable market insights across various industry verticals including chemicals and materials, healthcare, food and beverage, consumer goods, packaging, semiconductors, software and services, telecommunications and automotive. We offer syndicated market intelligence reports, customized research solutions and advisory services.
Consistent market information
1001 4th Ave, # 3200 Seattle, WA 98154, USA
Email: [email protected]
United States of America: + 1-206-701-6702
United Kingdom: + 44-020-8133-4027
Japan: + 050-5539-1737
India: + 91-848-285-0837